Efinopegdutide: What It Is, What the Research Shows, and Is It Approved?

Efinopegdutide shows up in the same conversations as Ozempic and the newer weight-loss drugs, but it's actually a bit of an outsider in that crowd. It's aimed mainly at your liver, not your waistline. And it's earlier in development than almost anything else people are talking about.

What efinopegdutide actually is

Efinopegdutide (lab code MK-6024, and before that HM12525A) is a peptide — that just means a short chain of amino acids, the tiny building blocks that make up protein. It's man-made, and it's designed to copy signals your body already uses.

Scientists call it a dual agonist. An *agonist* is something that switches a receptor on — picture a key that fits a lock. Efinopegdutide fits two locks:

• GLP-1 — the 'I'm full' signal. It's the same target as semaglutide (the drug in Ozempic and Wegovy). Switching it on curbs appetite and slows how fast food leaves your stomach.
• Glucagon — a signal that affects how your body burns energy, and that acts on the liver directly to burn fat and make less of it.

That glucagon half is the whole point here. The theory is that you can shrink liver fat two ways at once: indirectly, by helping someone lose weight, and directly, by telling the liver itself to burn fat rather than store it. That's why the drug's development has pointed at liver disease rather than the obesity market.

It was originally created by Hanmi Pharmaceutical, a South Korean company. It's now being developed by Merck, one of the largest drug companies in the US. The extra lab codes floating around online are leftovers from earlier owners — it's the same molecule.

What it's studied for

Efinopegdutide's trials are mostly about the liver:

• MASLD — metabolic dysfunction-associated steatotic liver disease. In plain English: fat building up in your liver when alcohol isn't the cause. It's very common and often silent.
• MASH — metabolic dysfunction-associated steatohepatitis. This is the nastier version: the fat inflames the liver and can scar it over time. Scarring is called *fibrosis*, and enough of it becomes *cirrhosis*, which is permanent damage.
• Obesity — studied, but it's a secondary story here, not the headline.

What the evidence really shows

Here's the honest summary: the early results are genuinely interesting, and there aren't many of them.

The standout study is a Phase 2a trial published in the *Journal of Hepatology* in 2023. It did something unusual and useful — instead of testing against a placebo (a dummy injection), it tested efinopegdutide head-to-head against semaglutide, a real approved drug. Researchers used MRI scans to measure how much fat was actually in people's livers.

Two things are worth sitting with. First, liver fat on a scan is not the same as getting better. It's what scientists call a *surrogate marker* — a stand-in that's easy to measure and hopefully predicts what you actually care about. What you actually care about is whether the liver stops being inflamed and scarred, and whether people live longer and healthier. A scan showing less fat is a promising hint, not proof.

Second, and this is the big one: efinopegdutide has never been in a Phase 3 trial. Not one. Phase 2 is the 'does this seem to work?' stage. Phase 3 is the large, long, expensive stage that has to pass before a regulator will even consider approving a drug. Efinopegdutide hasn't started that stage. Plenty of drugs that looked great at Phase 2 have died at Phase 3 — that's precisely why Phase 3 exists.

On side effects, the published trial reported slightly more adverse events on efinopegdutide than on semaglutide, and the difference was mostly gut-related — nausea, that sort of thing. Gut misery is the running theme across this entire family of drugs, and it isn't a footnote.

Who talks about it — and why to be careful

Efinopegdutide gets sold online precisely because it's obscure. The pitch tends to be some version of 'the one that beat Ozempic' — which leans on a single Phase 2 result, about liver fat on a scan, in 145 people. That's a real finding. It is not a reason to inject an unlabeled vial. And there's a particularly grim irony in buying an unregulated liver drug from an unknown source: your liver is the organ that has to process whatever contaminants are in there.

What this does not mean